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Abstract
Context: Adrenocortical carcinoma (ACC) is a rare and highly aggressive endocrine neoplasm, with limited therapeutic
options. Activating b-catenin somatic mutations are found in ACC and have been associated with a poor clinical outcome. In
fact, activation of the Wnt/b-catenin signaling pathway seems to play a major role in ACC aggressiveness, and might, thus,
represent a promising therapeutic target.
Objective: Similar to patient tumor specimen the H295 cell line derived from an ACC harbors a natural activating b-catenin
mutation. We herein assess the in vitro and in vivo effect of b-catenin inactivation using a doxycyclin (dox) inducible shRNA
plasmid in H295R adrenocortical cancer cells line (clone named shb).
Results: Following dox treatment a profound reduction in b-catenin expression was detectable in shb clones in comparison
to control clones (Ctr). Accordingly, we observed a decrease in Wnt/bcatenin-dependent luciferase reporter activity as well
as a decreased expression of AXIN2 representing an endogenous b-catenin target gene. Concomitantly, b-catenin silencing
resulted in a decreased cell proliferation, cell cycle alterations with cell accumulation in the G1 phase and increased
apoptosis in vitro. In vivo, on established tumor xenografts in athymic nude mice, 9 days of b-catenin silencing resulted in a
significant reduction of CTNNB1 and AXIN2 expression. Moreover, continous b-catenin silencing, starting 3 days after tumor
cell inoculation, was associated with a complete absence of tumor growth in the shb group while tumors were present in all
animals of the control group.
Conclusion: In summary, these experiments provide evidences that Wnt/b-catenin pathway inhibition in ACC is a promising
therapeutic target.
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Introduction
Adrenocortical carcinoma (ACC) is a rare and highly aggressive
endocrine neoplasm, with a 5-year overall survival of around 40%
[1–4]. Therapeutic options for these patients are scarce, and
available chemotherapies of limited effectiveness. A better
understanding of tumor biology and molecular prognostic factors
would help to select relevant therapeutic targets and to develop
innovative therapeutic strategies.
Activation of the Wnt/b-catenin signaling pathway in adreno-
cortical tumorigenesis has recently been investigated in detail [5–
10], and seems to play a major role in adrenocortical carcinoma
prognosis. In animal models, a constitutive activation of the Wnt/
b-catenin pathway in the adrenal cortex of transgenic mice leads
to the development of adrenocortical tumors with malignant
characteristics [11]. In humans, this pathway is frequently
activated mainly trough b-catenin gene (CTNNB1, i.e. Catenin
(cadherin-associated protein), beta 1) mutations [5,7], and is
associated with specific clinical and pathological characteristics
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and a poor outcome [8]. Likewise, a specific transcriptomic
signature of tumors with CTNNB1 mutation has recently been
shown [12], and might be responsible for the particular poor
prognosis of affected patients. Overall, these observations suggest
Wnt/b-catenin signaling pathway inactivation as a promising
therapeutic target in ACC.
The aim of this study was to assess the in vivo and in vitro effects of
Wnt/b-catenin signaling pathway specific inactivation using short
hairpin RNA (shRNA) in a tumor model for adrenocortical
carcinoma (H295R).
Materials and Methods
Cell Culture and generation of H295R Clones
Adrenocortical carcinoma cell line H295R stably transfected
with the Tet repressor (H295R/TR) was kindly provided by Dr.
Lalli [13]. Cells were grown as previously described [14]. pTer-b-
catenin vector, which expresses a doxycyclin inducible shRNA
targeted CTNNB1 (b-catenin; targeted sequence: 59-
GTGGGTGGTATAGAGGCTC-39) mRNA, and the control
vector (pTer) were obtained from Dr. van de Wetering [15].
H295R/TR were transfected with the pTer-b-catenin or pTer
and clones were selected by zeocin (50 mg/ml, InvivoGen). Three
shRNA-bcatenin clones (shb) were selected in which CTNNB1
expression was down-regulated at least 5 fold in a doxycyclin (dox,
0.2 mg/ml, Sigma) dependent manner in comparison to three
control clones (Ctr) transfected with pTer vector. All cell clones
were investigated for their ability to express specific steroidogenic
genes (StAR and CYP11B1) and their responses to the cAMP/PKA
pathway which was found to be comparable to that of the parental
cell line, H295R [16] (data not shown). S45P CTNNB1 (b-catenin)
gene activating mutation, previously identified in the parental
H295R cell line [5,8], was confirmed by direct sequencing in all
Ctr and shb clones (data not shown). While data are presented for
a single Ctr and shb clone all in vitro experiments were confirmed
with equivalent results in 2–3 individual clones (Ctr and shb).
Analysis of RNA and protein levels
Total RNA or protein extractions and analysis from cell lines
were performed as previously described [14] with primers and
antibodies described in Table S1.
Cell Transfection, and reporter assays
As a Wnt/b-catenin pathway reporter construct driving
expression of luciferase gene, the TopFlash plasmid (Top) was
used which contains two copies of the b-catenin/T-cell factor
TCF-binding sites whereas the FopFlash plasmid (Fop) contains
two mutated copies of the b-catenin/TCF-binding sites [5]. Rous
sarcoma virus (RSV)-Renilla (Promega) was used as a control of
transfection efficiencies. Cells were cotransfected and Firefly and
Renilla luciferase activities were sequentially measured as previ-
ously described [14].
Cell proliferation, cell cycle and apoptosis analysis
Proliferation was measured by MTT assay (Promega). The cell
cycle and apoptosis were analysed by flow cytometry as previously
reported [17].
Xenograft, pathological examination and
immunohistochemical staining
Female athymic NMRI nu/nu mice (6–8 weeks) were
purchased from Harlan Winkelmann (Borchen, Germany) and
housed under pathogen-free conditions. All experiments were
carried out following protocols approved by the Regierung von
Oberbayern and in accordance with the german guidelines for
animal studies. 156106 cells of the individual clones were
inoculated in a volume of 200 ml PBS subcutaneously into the
neck of each mouse. For short-term therapeutic experiments dox
treatment was initiated when the longest tumor diameters ranged
between 0.2–0.9 cm in size (after 21–31 days). Doxycyline was
added in a final concentration of 2 mg/ml to the drinking water in
amber water bottles. After 9 days of dox treatment tumors were
excised, fixed in formalin, embedded in paraffin, and 4 mm
sections cut and stained with Hematoxylin-Eosin-Saffron. Immu-
nohistochemistry for b-catenin was performed as previously
described [5]. Cells for long-term therapeutic experiments were
inoculated and 3 days after tumor induction mice were starting
from then continuously treated with dox water. Tumor size was
measured every other day using a calliper as described earlier [18].
At day 31 days after tumor induction, when first tumors reached a
longest tumor diameter of 1.5 cm, mice were sacrificed and
tumors excised.
Statistical analysis
All in vitro data with statistical analyses represent the quantifi-
cation of at least three experiments. Control conditions were set as
100% and data were analyzed using Fisher’s test. The statistical
analysis for comparison of tumor weight after long-term thera-
peutic experiment in vivo was performed by Mann-Whitney test.
Significance was set at P,0.05 (represented by * in figures);
P,0.01 (**) and P,0.001 (***).
Results
Efficient inactivation of CTNNB1 by shRNA in
adrenocortical cancer cells
H295R cells, harboring a heterozygous CTNNB1 gene mutation
on the GSK3b phosphorylation site (S45P), exhibit a constitutive
transcriptional activity of b-catenin-LEF/TCF [5]. Cell clones
expressing a doxycylin inducible shRNA targeting b-catenin were
generated. Two days following shRNA-b-catenin induction by
doxycyclin (dox) treatment, CTNNB1 mRNA (285%; p,0.01)
and protein levels were significantly decreased (figure 1-A). This
decrease in CTNNB1 mRNA and protein levels persisted with dox
treatment up to 10 days. In contrast, dox treatment had no effect
on CTNNB1 expression in control clone (Ctr) (figure 1-A).
CTNNB1 silencing decreases Wnt/b-catenin-LEF/TCF
dependent transcription
The Wnt/b-catenin-LEF/TCF dependent transcription was
studied by using the Top-Flash/Fop-Flash plasmids (Top and
Fop). As expected, transfected H295R cells showed higher
transcriptional activity of the b-catenin-LEF/TCF dependent
luciferase reporter construct Top in comparison to the mutated
Fop construct (figure 1-B, Ctr-Fop: 5% compared to Ctr-Top:
100%, p,0.01; and shb-Fop: 9% compared to shb-Top: 100%,
p,0.01). H295R cells which expressed shRNA-b-catenin (shb
with dox) showed lower transcriptional activity of the reporter
construct Top (shb-Top: 253%, p,0.01). Dox treatment did not
affect activity of the Top construct in the control clone (Ctr-Top)
or on the Fop construct with mutated LEF/TCF sites in both
clones (Ctr-Fop and shb-Fop).
Moreover, CTNNB1 silencing for two days significantly
decreased mRNA level of an endogenous canonical downstream
target gene of Wnt/b-catenin pathway, i.e AXIN2, in the shb clone
(figure 1-B, shb: 282%, p,0.01) compared to control clones (Ctr,
ns).
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CTNNB1 silencing alters proliferation, cell cycle and
apoptosis
A time course study of CTNNB1 silencing in H295R cell line
demonstrated a significant decrease in proliferation (245,8% at 12
days, p,0.05) compared to shb clone without CTNNB1 silencing
(2dox) or the control clone (figure 1-C), determined by MTT
conversion.
Flow cytometric analysis of cell cycle by propidium iodide
staining showed no effect on cell cycle until 5 days. However
following 10 days of dox treatment, CTNNB1 silencing resulted in
the accumulation of cells in the G1 phases and a decrease of cell
proportion in the S phase (figure 1-C, shb-10d-G1: 55.360.4% vs
65.862.2%; -S: 27.560.2% vs 16.561.6%, p,0.05). No such
difference was observed in the control clone (Ctr). At this time
point, we observed a reduction of two important proteins for G1/S
transition, Cyclin A and CDK2 only in cells silenced for CTNNB1
(figure 1-C).
Similarly, no effect on apoptosis assayed by the flow cytometric
analysis of annexine V incorporation in cells, was observed until 5
days while 10 days of dox induced CTNNB1 silencing increased the
proportion of apoptotic cells (figure 1-C, shb-10d: 167%, p,0.05)
when compared to cells without dox treatment. No such difference
was observed in the control clone. This increase of apoptosis by
CTNNB1 silencing was also confirmed by the gain of a
proapoptotic protein level, cleaved caspase3 (cc3), which was
detectable already at an earlier time point (5 days, figure 1-C).
Likewise, CTNNB1 silencing increased the apoptotic effect of
staurosporin (figure 1-C; shb-5d+stau: 224% vs 377%, p,0.05)
while no significant difference was observed in control clones.
CTNNB1 silencing abolish xenograft development of ACC
cell line
To evaluate the functional significance of b-catenin knock-down
on tumor development we proceeded with investigation in a
subcutaneous xenograft tumor model in athymic nude mice.
In a first step, short term experiments with CTNNB1 inactiva-
tion on established tumors (21 to 31 days after xenografting) for a
duration of 9 days were performed to mirror the time course from
our in vitro experiments (figure 1-C). Similar to the in vitro setting
mRNA expression analyzes revealed a dox dependent significant
decrease in tumoral CTNNB1 and AXIN2 expression in shb clone
(figure 2-A; CTNNB1:289%, p= 0.007; AXIN2:287%, p,0.001)
while control clones remained unaffected by dox treatment.
Moreover, and in accordance with the cell culture experiments,
immunohistochemical analysis (figure 2-B) revealed a dox treat-
ment dependent reduction of b-catenin protein. But, we have not
Figure 1. CTNNB1 silencing alters the Wnt/b-catenin signaling pathway, proliferation, cell cycle and apoptosis. A, Histogram and
Western blot panels represent CTNNB1 (b-catenin) mRNA and protein accumulation, in Ctr and shb clones after 2, 5 or 10 days after addition of
doxycyclin (dox) in the culture medium (0.2 mg/ml). B-left, cells were transiently co-transfected with an artificial Wnt/-b-catenin pathway reporter
construc (Top) or his control mutated (Fop). After 24 h, cells were treated by vehicle or dox (0.2 mg/ml) for 24 h and luciferase activity was measured.
-right, Histogram represent AXIN2 mRNA accumulation after 2 days of dox treatment. C-left, Cell survival curve of cells, as assessed by the MTT assay
without or with dox (0.2 mg/ml) for 1, 4, 8 or 12 days. -center, The distribution of cells in the various phases of the cell cycle was analysed by flow
cytometric analysis of propidium iodide staining after vehicle or dox treatment for 2, 5 and 10 days. Western blots show b-catenin, CyclinA and CDK2
protein levels at 10 day. -right, Histograms represent apoptotic cells measured by flow cytometric annexin V incorporation, after vehicle or dox
treatment for 2, 5 and 10 days, without or with staurosporin co-treatment for last 6 h (0.5 mg/ml). Western blots show the cleaved caspase 3 (cc3) in
same condition.
doi:10.1371/journal.pone.0055743.g001
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observed any differences for the Ki67 and the cleaved caspase3
expression by immunohistochemistry analyzes (data not shown),
suggesting that 9 days of dox is not sufficient in vivo to induce
effects on proliferation and on apoptosis. Because this time course
is too short to investigate a potential effect on tumor growth in an
in vivomodel, long term dox treatment was performed. Ctr and shb
clones were subcutaneously injected and 3 days after tumor
induction mice were treated with dox in a continuous manner.
There is no significant difference after 31 days in tumor size
between shb and Ctr clones in absence of dox treatment, but it’s
seem that the shb clone grow slower than the Ctr clone, probably
because of a clonal effect. For this reason the doxycyclin-inducible
system is suitable, because the clones are their own control. While
dox treatment did not affect tumor growth and weight in the
control clone (figure 2-C-left, medians weight: 112 mg vs
162.7 mg, ns), there was a significant impact of CTNNB1 silencing
upon dox treatment in the shb clone (figure 2-C-rigth). Indeed, for
shb clone, during the first 10 days, tumor growth was observable
Figure 2. CTNNB1 silencing abolish xenograft development of ACC cell line. A, Histograms represent CTNNB1 (b-catenin) and AXIN2 mRNA
accumulation in xenograft for both Ctr (2dox n= 6; +dox, n = 5) and shb (2dox, n = 5; +dox, n = 5) clones on established tumors and after 9 days of
dox treatment. B, hematoxylin–eosin–saffron and b-catenin, staining (620) on representative tumors of shb clone without and with dox treatment
(same experiment as B). C, Boxplots represent the tumor sizes for Ctr and shb xenografts in mice continuously treated with vehicle or dox after 3 days
of tumor induction. Boxplots in the left corner represent the weights of tumors excised. Ctr (2dox n= 7, + dox n= 8), shb (2dox, n = 7; +dox, n = 8).
doi:10.1371/journal.pone.0055743.g002
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in both groups (without or with dox) but, after 13 days, no tumor
was detectable in any of the mice of shb group treated with dox,
including after dissection and pathological analysis (figure 2-C-
rigth, median weight 67.4 mg vs 0 mg, p,0.001).
Discussion
In many cancers, the Wnt/b-catenin signalling pathway plays
an important role regulating cell growth, motility, and differen-
tiation [19]. We and others have previously demonstrated the
importance of the Wnt/b-catenin signaling pathway activation in
adrenal cortex tumorigenesis [5–10]. This activation is associated
with a specific molecular signature and a worse outcome with
lower overall survival [12]. Doghman and colleagues previously
showed that a TCF antagonist inhibits proliferation of adreno-
cortical cells H295R, suggesting a central role of Wnt/b-catenin
pathway in adrenocortical tumorigenesis [20]. However, this
pharmacological approach might not be specific for Wnt signaling.
We herein, using both in vitro and in vivo experiments, demonstrate
that direct and specific b-catenin inactivation lead to alterations of
proliferation, cell cycle and apoptosis which lead to a dramatic
decrease in tumor development in a tumor model for ACC.
Further experiments are needed in order to know if b-catenin
inactivation suppresses the growth or prevents engraftment of the
cells. Nevertheless, these results confirm 1/the biological conse-
quence of Wnt/b-catenin pathway activation in adrenocortical
tumorigenesis, and 2/the major therapeutic interest to target this
pathway.
Inhibition of Wnt/b-catenin pathway in a subgroup of
aggressive ACC seems to be a interesting therapeutic target and
should be evaluated in more detail in the future.
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